A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

Trial Profile

A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Upadacitinib (Primary) ; Abatacept
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT-CHOICE
  • Sponsors AbbVie
  • Most Recent Events

    • 31 Oct 2017 Planned End Date changed from 26 Mar 2021 to 29 Mar 2021.
    • 31 Jul 2017 Planned End Date changed from 29 Apr 2021 to 26 Mar 2021.
    • 28 Jun 2017 Planned End Date changed from 25 Mar 2021 to 29 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top